Dermapharm Holding SE (CHIX:DMPD) Retained Earnings: €561 Mil (As of Mar. 2026)


CHIX:DMPD Dermapharm Holding SE CHIX:DMPD
80 GF Score
Price €46.18
GF Value €39.39
! 9 Warning Signs
View Full Analysis

What is Dermapharm Holding SE Retained Earnings?

Dermapharm Holding SE CHIX:DMPD 80 Retained Earnings is €561 Mil as of Mar. 2026. GuruFocus rates CHIX:DMPD with a GF Score™ of 80/100 and a GF Value™ of €39.39. The stock has 9 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Dermapharm Holding SE's retained earnings for the quarter that ended in Mar. 2026 was €561 Mil.

Dermapharm Holding SE's quarterly retained earnings increased from Sep. 2025 (€479 Mil) to Dec. 2025 (€516 Mil) and increased from Dec. 2025 (€516 Mil) to Mar. 2026 (€561 Mil).

Dermapharm Holding SE's annual retained earnings increased from Dec. 2023 (€367 Mil) to Dec. 2024 (€433 Mil) and increased from Dec. 2024 (€433 Mil) to Dec. 2025 (€516 Mil).


Dermapharm Holding SE  (CHIX:DMPd) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Dermapharm Holding SE Retained Earnings Historical Data

* Premium members only.

The historical data trend for Dermapharm Holding SE's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dermapharm Holding SE Retained Earnings Chart

Dermapharm Holding SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 337.95 355.36 367.22 433.19 515.91

Dermapharm Holding SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 466.60 437.80 479.03 515.91 561.11
CHIX:DMPD
80GF Score
Dermapharm Holding SE CHIX:DMPD
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dermapharm Holding SE Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €561 Mil mean?
Dermapharm Holding SE (CHIX:DMPD) has a Retained Earnings of €561 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Dermapharm Holding SE and its competitors.
Is Dermapharm Holding SE's Retained Earnings too high?
Dermapharm Holding SE's current Retained Earnings is €561 Mil. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Retained Earnings compare to ZTS and UTHR?
Dermapharm Holding SE's Retained Earnings of €561 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Dermapharm Holding SE and its competitors. Dermapharm Holding SE's current Retained Earnings is €561 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current Retained Earnings of €561 Mil. The stock's GF Value™ is €39.39, compared to a current price of €46.18 — trading 17.2% above its estimated fair value. The current Retained Earnings is €561 Mil. Dermapharm Holding SE's overall GF Score™ is 80/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current Retained Earnings is €561 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?

Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued. The current stock price of €46.18 is trading 17.2% above its estimated GF Value™ of €39.39.

Key valuation signals for CHIX:DMPD:

  • Retained Earnings: €561 Mil
  • GF Value™: €39.39 vs. price of €46.18 (17.2% above fair value)
  • GF Score™: 80/100 with 9 warning signs

No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dermapharm Holding SE Business Description

Other Exchanges DMPHF:USA0A5J:UKDMP:Germany
Address Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score

Get the complete analysis for CHIX:DMPD

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.18
Price
€39.39
GF Value